Literature DB >> 28073780

Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp.

Iram Ahmad1,2, Leila R Zelnick2, Nicole R Robinson2, Adriana M Hung3, Bryan Kestenbaum2, Kristina M Utzschneider4,5, Steven E Kahn4,5, Ian H de Boer2,5.   

Abstract

Insulin sensitivity can be measured by procedures such as the hyperinsulinemic euglycemic clamp or by using surrogate indices. Chronic kidney disease (CKD) and obesity may differentially affect these measurements because of changes in insulin kinetics and organ-specific effects on insulin sensitivity. In a cross-sectional study of 59 subjects with nondiabetic CKD [estimated glomerular filtration rate: (GFR) <60 ml·min-1·1.73 m2] and 39 matched healthy controls, we quantified insulin sensitivity by clamp (SIclamp), oral glucose tolerance test, and fasting glucose and insulin. We compared surrogate insulin sensitivity indices to SIclamp using descriptive statistics, graphical analyses, correlation coefficients, and linear regression. Mean age was 62.6 yr; 48% of the participants were female, and 77% were Caucasian. Insulin sensitivity indices were 8-38% lower in participants with vs. without CKD and 13-59% lower in obese compared with nonobese participants. Correlations of surrogate indices with SIclamp did not differ significantly by CKD or obesity status. Adjusting for SIclamp in addition to demographic factors, Matsuda index was 15% lower in participants with vs. without CKD (P = 0.09) and 36% lower in participants with vs. without obesity (P = 0.0001), whereas 1/HOMA-IR was 23% lower in participants with vs. without CKD (P = 0.02) and 46% lower in participants with vs. without obesity (P < 0.0001). We conclude that CKD and obesity do not significantly alter correlations of surrogate insulin sensitivity indices with SIclamp, but they do bias surrogate measurements of insulin sensitivity toward lower values. This bias may be due to differences in insulin kinetics or organ-specific responses to insulin.
Copyright © 2017 the American Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28073780      PMCID: PMC5374297          DOI: 10.1152/ajpendo.00394.2016

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  34 in total

1.  Fasting insulin reflects heterogeneous physiological processes: role of insulin clearance.

Authors:  Mark O Goodarzi; Jinrui Cui; Yii-Der I Chen; Willa A Hsueh; Xiuqing Guo; Jerome I Rotter
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-31       Impact factor: 4.310

2.  Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease.

Authors:  J Piekarski; H I Goldberg; S A Royal; L Axel; A A Moss
Journal:  Radiology       Date:  1980-12       Impact factor: 11.105

3.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

4.  Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.

Authors:  R A DeFronzo; R Gunnarsson; O Björkman; M Olsson; J Wahren
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

5.  Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease.

Authors:  Thomas Idorn; Filip K Knop; Morten Jørgensen; Jens J Holst; Mads Hornum; Bo Feldt-Rasmussen
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

6.  Impact of degree of obesity on surrogate estimates of insulin resistance.

Authors:  Sun H Kim; Fahim Abbasi; Gerald M Reaven
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

7.  Quantitative study of insulin secretion and clearance in normal and obese subjects.

Authors:  K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

8.  Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man.

Authors:  S Del Prato; F Leonetti; D C Simonson; P Sheehan; M Matsuda; R A DeFronzo
Journal:  Diabetologia       Date:  1994-10       Impact factor: 10.122

9.  Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study.

Authors:  C Christine Lee; Steven M Haffner; Lynne E Wagenknecht; Carlos Lorenzo; Jill M Norris; Richard N Bergman; Darko Stefanovski; Andrea M Anderson; Jerome I Rotter; Mark O Goodarzi; Anthony J Hanley
Journal:  Diabetes Care       Date:  2012-12-05       Impact factor: 19.112

10.  Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis.

Authors:  Giacomo Garibotto; Antonella Sofia; Rodolfo Russo; Ernesto Paoletti; Alice Bonanni; Emanuele L Parodi; Francesca Viazzi; Daniela Verzola
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

View more
  3 in total

1.  The kidney's role in systemic metabolism-still much to learn.

Authors:  Ian H de Boer; Kristina M Utzschneider
Journal:  Nephrol Dial Transplant       Date:  2017-04-01       Impact factor: 5.992

2.  Chronic kidney disease attenuates the plasma metabolome response to insulin.

Authors:  Baback Roshanravan; Leila R Zelnick; Daniel Djucovic; Haiwei Gu; Jessica A Alvarez; Thomas R Ziegler; Jorge L Gamboa; Kristina Utzschneider; Bryan Kestenbaum; Jonathan Himmelfarb; Steven E Kahn; Daniel Raftery; Ian H de Boer
Journal:  JCI Insight       Date:  2018-08-23

Review 3.  Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs.

Authors:  Meihui Wang; Zixu Wang; Yaoxing Chen; Yulan Dong
Journal:  Int J Mol Sci       Date:  2022-01-11       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.